KI- Mayo Collaborative grant recipients
The grant recipients for the collaborative call for applications to support research in Breast Cancer, other Solid Tumors, and Hematologic Malignancies was announced on June 2023.
The objective of this funding is to provide support to initiate and enhance collaborations in cancer research between Mayo Clinic Cancer Center and Karolinska Institutet - Cancer Research KI. In 2023, the grants supports research in breast cancer, other solid tumors, and hematologic malignancies.
These studies may involve considerable scientific risk but may potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research and patient outcomes. It is expected that support via this program will lead to subsequent extramural support from other sources, and will be a metric of success for this grant-awarding program.
For 2023, three individual projects were awarded for one year with a second year of funding contingent on satisfactory progress in the first year.
Project investigators may request up to $100,000 (total cost) for the Mayo Clinic Cancer Center component ($50,000/year for 2 years) and up to 1 MSEK for the Karolinska Institutet component (625,000 SEK/year for 2 years) per project. Indirect costs are included in the total award. More information can be found here.
2023 grant recipients
|Department of Medical Biochemistry and Biophysics
|Discovery of new therapies for the treatment of estrogen receptor positive breast cancer
|Department of Laboratory Medicine
|Development of extracellular vesicle biomarkers for CART cell functions in lymphoma
|Department of Cell and Molecular Biology
|Roberto Leon Ferre
|Development of novel computational approaches to interpret and leverage multi-organ single-cell spatial profiling for comprehensive characterization of the triple-negative breast cancer tumor microenvironment
2022 grant recipients
|Dept. of Microbiology, Tumor and Cell Biology
|Mutant p53 as a target to improve response to immune checkpoint blockade
|Dept. of Oncology-Pathology
|Pseudo-Mutant p53: a Predictor of Leukemic Transformation in Clonal Hematopoiesis
|Dept. of Medical Epidemiology and Biostatistics
|Artificial intelligence image-based model development and validation for long-term breast cancer risk assessment in Swedish and U.S. screening setting
|Dept. of Biosciences and Nutrition
|Zhi Zhang Yang
|Development of targeted immunotherapy for malignant B cell lymphomas
|Richard Rosenquist Brandell
|Dept. of Molecular Medicine and Surgery
|Multi-Omics Studies of BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia
2021 grant recipients
In 2022, these two project were extended for a second year of funding for their collaborative breast cancer research projects.
|“Novel NOTCH3-Based Therapies to Inhibit the Growth and Immune Evasion Capacity of Triple Negative Breast Cancer”
|“Exploration of fibroblasts as biologically relevant biomarkers in breast benign disease”
2020 grant recipient
|”Identification of genetic variants as predictors of hematological toxicity of adjuvant chemotherapy in breast cancer”